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Abstract  
 
Dysregulation of the serotonergic system and abnormalities of the 
hypothalamic-pituitary-adrenal axis have been demonstrated in major depression. 
Animal studies indicate that 5-HT1A receptor expression may be reduced by long-
term administration of corticosterone. However, similar studies on the regulation of 
GIRK channels, one of the most important effectors of the neuronal 5-HT1A receptor, 
are limited. In order to address these issues, slow-release corticosterone pellets were 
implanted subcutaneously to adrenal intact male rats (200 mg pellets, 35 days 
release). Starting on day 15, animals were treated for 21 days with fluoxetine 
(5mg/kg/day, i.p), or vehicle. Using in situ hybridization histochemistry and receptor 
autoradiography, we found that chronic corticosterone treatment was accompanied 
by a significant decrease on the mRNAs coding for mineralocorticoid receptors in 
hippocampal areas. Under these conditions, 5-HT1A receptor mRNA expression 
decreased in dorsal raphe nucleus and dentate gyrus. However, 5-HT1A receptor 
levels, as measured by [3H]-8-OH-DPAT binding, diminished significantly only in 
dentate gyrus. It is noteworthy that chronic treatment with fluoxetine reversed the 
alterations on 5-HT1A receptor mRNA levels only in dorsal raphe. Finally, chronic 
corticosterone treatment produced an increase on the mRNA coding for the GIRK2 
subunit in several hypothalamic and thalamic areas, which was reversed by 
fluoxetine. Measurements of cell density and volume of the granular layer of the 
dentate gyrus did not reveal significant changes after corticosterone or corticosterone 
plus fluoxetine treatments. These data are relevant for a better understanding of the 
differential regulation of pre- and postsynaptic 5-HT1A receptors by corticosterone 
flattened rhythm. 
 
Key words (6): mineralocorticoid receptor; glucocorticoid receptor; corticosterone 
flattened rhythm; depression; [3H]-8-OH-DPAT binding; hippocampus 
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1. Introduction  
 
Major depression is, perhaps, one of the most compelling examples of a 
stress-related disorder with evidence of both reduced glucocorticoid responsiveness 
and dysregulation of the serotonergic system. Glucocorticoid hypersecretion, in 
conjunction with reduced glucocorticoid responsiveness, is a common and reliable 
finding in patients with major depression (Holsboer, 2000). Successful antidepressant 
treatment is associated with normalization of altered glucocorticoid-mediated 
inhibitory feed-back in these patients, as assessed by either the dexamethasone 
suppression test or dexamethasone-corticotropin releasing hormone test (Holsboer, 
2000). 
Animal models can provide important insights in order to address mechanisms 
of depression and anxiety. Overall, results from different gene knockout models 
implicate 5-HT1A receptors in anxiety behaviours (Parks et al., 1998; Santarelli et al., 
2003). Interestingly, the expression of 5-HT1A receptors is decreased by 
corticosteroid hormones in a variety of animal studies, whereas removal of circulating 
corticosteroids by adrenalectomy up-regulates 5-HT1A receptor expression (Chalmers 
et al., 1993; Meijer et al., 1997b; Meijer and de Kloet, 1994; Mendelson and McEwen, 
1992). In the literature there are also diverging findings as regarding to extent of 5-
HT1A receptor expression regulation (see Holmes et al. (1995)). Over the last years, a 
rat model of flattened glucocorticoid-rhythm induced by subcutaneous implantation of 
corticosterone pellets has been carefully characterized and validated (Gartside et al., 
2003a; Gartside et al., 2003b; Leitch et al., 2003). Such pellets provide a steady, 
continuous corticosterone exposure leading to the loss of circadian fluctuation 
(Akana et al., 1992; Leitch et al., 2003; Young et al., 1995). The levels of blood 
corticosterone achieved are within the physiological range (midway between nadir 
and zenith) but the overall glucocorticoid daily exposure is unchanged (Leitch et al., 
2003). Elevated nadir and flattened rhythm are consistent with the pattern observed 
in depressed patients, although in humans the peak of the diurnal rhythm is 
preserved, or even elevated, resulting in an increase in total cortisol exposure during 
the day (Holsboer, 2000). Using the corticosterone pellet rat model, Leitch et al. 
(2003) demonstrated desensitization of somatodendritic 5-HT1A autoreceptors, but 
the mechanisms underlying these changes, i.e. expression of receptor and/or 
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effectors, have not been addressed yet. The effects of corticosterone upon 5-HT1A 
receptors could result from actions of mineralocorticoid (MR) and/or glucocorticoid 
receptors (GR) directly on the promoter region of the 5-HT1A receptor gene or 
through interactions with other regulatory proteins (Ou et al., 2001; Wissink et al., 
2000). Nothing is known either about the effects of such treatments on G-protein 
inwardly rectifying potassium (GIRK) channels, which are activated by 5-HT1A 
receptors (Zgombick et al., 1989) and are expressed in most 5-HT1A receptor mRNA-
containing cells in brain areas such as hippocampus, cerebral cortex, septum and 
dorsal raphe nucleus (Saenz del Burgo et al., 2008). In this respect, it is of note that 
the study by Karten et al. (1999) shows that the loss of CA1 hippocampal 5-HT1A 
responsiveness induced by long-term exposure to corticosterone was not 
accompanied by alterations on 5-HT1A receptor mRNA expression.  
Considering the above evidence, the purposes of this study were i) to study 
the effects that these alterations in circulating corticosterone might have on the 
expression of MR and GR mRNAs; ii) to monitor possible impairments in the 
expression of brain mRNAs coding for GIRK1-3 subunits and 5-HT1A receptors 
following long-term exposure to flattened corticosterone rhythm and iii) to analyze the 
effects of chronic fluoxetine treatment in this rat model, which shows elevated plasma 
corticosterone levels and presumably dysregulated MR and GR signalling. In this 
context, studies in “normal” animals (i.e. unstressed) have demonstrated that long-
term fluoxetine administration increases the expression of corticosteroid receptors 
(Bjartmar et al., 2000; Brady et al., 1992) but does not alter 5-HT1A receptor mRNA 
not 3H-8-OH-DPAT binding levels (Hervás et al., 2001). However, no attempts have 
been made to assess the regulatory effects of fluoxetine upon corticosteroid 
receptors under the persistent presence of a relatively high circulating level of 
corticosterone. Since many depressed patients with a pre-existing flattening of their 
glucocorticoid rhythm will be prescribed fluoxetine as a treatment for their 
depression, this potential interaction may be of therapeutic importance. In this sense, 
previous studies show that flattened glucocorticoid rhythm compromises the ability of 
fluoxetine to elevate forebrain 5-HT levels (Gartside et al., 2003b), an effect that 
could be necessary for the up-regulation of corticosteroid receptors induced by 
fluoxetine, and that might explain the limited efficacy of fluoxetine in patients with 
abnormal hypothalamic-pituitary adrenal (HPA) axis function (Young et al., 2004). 
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2. Experimental procedures  
2.1. Animals  
Male albino Sprague-Dawley rats (200–250 g b.w.) were obtained from Harlan 
Iberica (Barcelona, Spain). Animals were kept in a controlled environment (12-hour 
light-dark cycle, lights on at 08:00 hours, and 22 ± 2°C room temperature) with ad 
libitum access to food and water. Rats were handled following the European Union 
regulations (O.J. of E.C. L358/1 18/12/1986). 
 
2.2. Chronic treatments 
Three groups of individually housed rats underwent implantation of 
corticosterone pellets or sham surgery under chloral hydrate anaesthesia. 
Commercial corticosterone pellets (Innovative Research of America, USA) designed 
to release 200 mg of corticosterone over 35 days (5.7 mg/day) were used. Rats were 
weighed every day. From day 15th after surgery on, at around 10:00 am, one group of 
animals treated with corticosterone received daily ip. injections of fluoxetine (5 mg/kg 
i.p. in saline) for 21 days. Another group of rats treated with corticosterone and the 
sham group received ip. injections of saline. Animals were killed at 12.00 pm on day 
36 after surgery. The selected dose of fluoxetine is within the range used by others to 
produce plasma concentrations of fluoxetine similar to those obtained in patients 
treated with clinical doses of this antidepressant (Unceta et al., 2007).  
 
2.3. Tissue preparation 
Rats were decapitated and trunk blood was collected for subsequent analysis 
of serum corticosterone. Brains were removed, frozen on dry ice and stored at -20ºC 
to be used for in situ hybridization and receptor autoradiography. Tissue sections, 14 
µm thick, were cut using a microtome-cryostat (HM500 OM; Microm, Walldorf, 
Germany), thaw-mounted onto 3-aminopropyltriethoxysilane (APTS; Sigma) coated 
slides, and kept at -20°C. 
 
2.4. Serum corticosterone assay 
Trunk blood samples were left to coagulate on ice, centrifuged at 1,300xg for 
15 minutes, and the resultant serum removed. Samples were stored at -80ºC until 
analysis for corticosterone using a commercial radioimmunoassay kit (Coat-a-count 
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Rat Corticosterone DPC, Los Angeles, CA, USA). 
 
2.5. In situ hybridization 
The oligodeoxyribonucleotide probes used to detect GIRK1, GIRK2, GIRK3 
and 5-HT1A receptor mRNA have been described elsewhere (Saenz del Burgo et al., 
2008). For GR mRNA, two oligonucleotides were used simultaneously that were 
complementary to bases 2221-2265 and 2345-2389 (GenBank acc. no. M14053.1). 
MR mRNA was detected using one oligonucleotide probe complementary to bases 
3356-3400 (GenBank acc. no. M36074).  
The oligonucleotides were synthesized and HPLC-purified by Isogen 
Bioscience (Maarsden, The Netherlands). Evaluation of the oligonucleotide 
sequences with the basic local alignment search tool of EMBL and Gen-Bank 
databases indicated that the probes do not show any significant similarity with 
mRNAs other than their corresponding targets in the rat. Oligonucleotide probes 
were labeled at the 3´-end using [α-33P]dATP (3,000 Ci/mmol; New England Nuclear, 
Boston, MA) and terminal deoxynucleotidyltransferase (Oncogene Research 
Products, San Diego, CA), and then purified by using QIAquick Nucleotide Removal 
Kit (Qiagen, Hilden, Germany).  
The protocol for in situ hybridization histochemistry was based on previously 
described procedures and has been already published (Saenz del Burgo et al., 2008 
and references therein). The incubated sections were exposed to Biomax-MR 
(Kodak) films for 1-2 weeks at -80°C with intensifying screens to obtain 
autoradiograms. The average densities of each mRNA in different brain regions were 
evaluated semiquantitatively on film autoradiograms with the aid of an image analysis 
system (AIS, Imaging Research Inc., St. Catherines, Canada).  
 The specificity of the hybridization signal obtained was confirmed in a series of 
routine controls including 1) different oligonucleotide probes directed against different 
regions of the same mRNA gives identical hybridization patterns when used 
independently; 2) hybridization signal of a given 33P-labeled probe is abolished in the 
presence of an excess of the same unlabeled probe in the hybridization solution; 3) 
thermal stability of the hybrids examined by washing at increasing temperatures 
shows a sharp decrease in hybridization signal at a temperature consistent with their 
Tm. Autoradiographic images of control experiments are shown in supplementary 
Figs. S1 and S2.. 
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2.6. Receptor autoradiography 
Sections were preincubated for 10 minutes at room temperature in 170 mM 
Tris-HCl (pH 7,6), 4 mM CaCl2, and 0.01% ascorbic acid and then incubated for 1 
hour at room temperature in [3H]-8-OH-DPAT (230 Ci/mmol; Amersham, U.K.) in the 
same buffer (Pazos and Palacios, 1985). Non-specific binding was defined in the 
presence of 10-5 mM 5-HT. Sections were washed twice (5 min each) in the same 
buffer at 4°C, dipped in distilled water at 4°C, and rapidly dried under cold air. 
Tissues were exposed to Biomax MR (Kodak) films together with plastic standards 
(3H-Microscales; Amersham) for 2 months. Quantitative analysis of the 
autoradiograms was performed with a computerized image analysis system (AIS, 
Imaging Research Inc., St. Catherines, Canada). 
 
2.7. Figure preparation 
The AIS image analysis system was used to capture pseudocolor images from 
in situ hybridization or receptor autoradiography films. The images were prepared for 
publication using Adobe Photoshop software (Adobe Systems, San Jose, CA) 
without modifications. 
 
2.8. Analysis of the volume of the granular layer of the dentate gyrus 
A set of animals from the three treatment groups (n=5 each) was processed 
for analysis of volume and cell density in the granular layer of the dentate gyrus 
(DGgl). The rats were deeply anesthetized with an overdose of chloral hydrate 
(1 g/kg, i.p.) and perfused transcardially with 0.1 M phosphate-buffered saline (PBS), 
pH 7.4, followed by 4% paraformaldehyde in 0.1 M PB, pH 7.4. Subsequently, the 
brains were removed and immersed in the same fixative for 4 h at 4ºC, and then 
transferred to PBS containing 30% sucrose, maintained in the fridge until they sunk 
and then frozen in isopentane at -80°C. Whole series of 40 µm thick frozen coronal 
sections were obtained using a microtome (Leitz-Wetzlar 1310, Wetzlar, Germany) 
provided with a specific temperature sensor (5MP BFS-Physitemp Controller, Clifton, 
New Jersey, USA). A section-sampling fraction of 1/10 was used for volume 
estimation. Tissue sections from all groups were mounted on gelatin-coated slides, 
allowed to dry, and processed simultaneously for Nissl staining with identical 
incubation solutions. Sections were then coverslipped with DPX and examined with 
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an Olympus BX50F optic microscope (Olympus, Tokyo, Japan) equipped with a high-
resolution digital camera (Olympus and Soft Imaging Systems, Tokyo, Japan). 8-bit 
gray scale images of the hippocampus were taken under a 4X objective and digitised 
using CellA software for image acquisition with identical illumination and exposure 
settings (Olympus and Soft Imaging Systems, Tokyo, Japan). Thereafter, all images 
were converted to black and white particles by setting an identical “threshold” using 
ImageJ image analysis software (ImageJ, NIH, Bethesda, MD, USA). The resulting 
binary images were edited further in Photoshop to remove particles outside the DGgl. 
Finally, percent area fraction measurements using ImageJ allowed us to calculate the 
area corresponding to DGgl in each of the acquisitions. The total volume for the DGgl 
was estimated using Cavalieri’s principle (Gundersen and Jensen, 1987), by 
multiplying the total area measured in each section by the distance between 
consecutive sections of the 1/10 sampling fraction (400 µm). See supplementary 
figures for further details concerning measuring methods. 
 
2.9. Analysis of cell density in the granular layer of the dentate gyrus 
Four 40 µm thick frozen coronal sections per animal, collected between 
bregma -4.0 and 5.5 mm (with 400 µm distance between sections), were mounted on 
gelatin-coated slides, allowed to dry, and simultaneously processed with Hoescht 
33342 (Sigma-Aldrich; 1 µg/ml in PBS containing 0.1% Triton X-100 for 15 min). 
Sections were then coverslipped with Mowiol and images of lateral and medial 
blades of the DGgl were captured with a fluorescence microscope (Carl Zeiss Axio 
Observer) equipped with a structured illumination module (ApoTome) and a XYZ 
motorized stage. The objective used was a 20X Zeiss Plan-Apochromat 0.80 NA. 
Acquired images were rotated and cropped to fit the DGgl in a counting box of 300 
µm x 100 µm. For the analysis, two sampling areas per section and side (left and 
right) were selected. Thus, a total of 8 sampling areas per animal and side (right and 
left) in a total of 15 specimens (n=5 per group) were used for quantification. An 
observer blind to the treatment counted directly on microscope images the number of 
neuronal nuclei, which could be distinguished from glial nuclei based on their larger 
size, slightly granulated staining and looser chromatin. Data were expressed as 
number of cells per mm2. See supplementary figures for further details concerning 
measuring methods. 
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2.10. Statistical analysis 
GraphPad Prism 4.01 (GraphPad Software Inc., San Diego, CA) was used to 
organize and analyze data. Statistical significance of treatment effects on weight 
gain, plasma corticosterone and adrenal gland weight was determined using one-way 
ANOVA followed by Tukey–Kramer's test, with p<0.05 considered significant in all 
cases. Overall effects of corticosterone treatment with or without fluoxetine 
administration on the in situ hybridization signal for each mRNA species and 3H-8-
OH-DPAT binding in each brain region analyzed were tested by two-way ANOVA. 
The data were analyzed considering the effect of treatment (sham, corticosterone 
and corticosterone plus fluoxetine), the anatomical region and treatment×region 
interaction. Since the anatomical region factor was statistically significant for all 
variables examined (mRNAs encoding MR, GR, 5-HT1A receptor and GIRK1-3, as 
well as 3H-8-OH-DPAT binding) (P<0.0001), we report only P values corresponding 
to treatment×region interaction when P<0.05, or treatment factor (if P<0.05) when 
treatment×region interaction was P<0.05. Further analysis was done with post hoc 
Bonferroni test to determine the source of the detected significances in the ANOVAs. 
Statistical data are reported in the figure legends. 
 
3. Results 
3.1. Effects of treatments on animal-growth  
 Animals were monitored daily at 9 a.m. to control body weight. The time course of 
all animal groups is shown in Supplementary Fig. S3. Over the postoperative period 
all experimental groups suffered a marked weight loss, which was consistently more 
pronounced in corticosterone-treated animals. As shown in Fig. 1A, weight gain was 
significantly smaller in rats that received corticosterone (groups CORT and 
CORT+FLX) than in the corresponding sham-operated animals between days 5 and 
15 of treatment (P<0.01 in all cases). While sham animals started to recover weight 
around day 5 after surgery, the two groups of animals that received chronic 
corticosterone treatment showed no weight gain or even weight loss during days 5 to 
15, and a reduced weight gain between days 5 to 36 (in all instances P<0.01 in 
comparison to sham group 1) (Fig. 1A).  
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3.2. Determination of plasma corticosterone levels and effects of treatments on 
adrenal weight  
In order to validate our animal model, hormone plasma levels were evaluated 
by radioimmunoassay in blood samples collected at the moment of sacrifice. As 
shown in Fig. 1B, plasma corticosterone levels were significantly higher in 
corticosterone-treated animals than in sham-operated animals. Plasma 
corticosterone levels were elevated in both chronically treated groups, independently 
of the concomitant fluoxetine treatment. As shown in Fig. 1C, there was a significant 
reduction in the adrenal glands’ average weight after chronic corticosterone 
treatment, independently of the concomitant fluoxetine treatment.  
 
3.3. Effects of treatments on mineralocorticoid and glucocorticoid receptor 
mRNA expression  
Mineralocorticoid (MR) and glucocorticoid (GR) receptor mRNA expression 
was examined in several areas across the brain, as reported in Fig. 2. Chronic 
corticosterone treatment induced significant and selective decreases in MR mRNA 
expression in the hippocampal CA1-4 region (CA) and dentate gyrus (DG). In 
contrast, chronic corticosterone treatment failed to alter GR mRNA levels in the 
hippocampus and dentate gyrus but selectively reduced expression in the granular 
layer of the cerebellum (CbGr). Concurrent treatment with fluoxetine did not modify 
corticosterone effects on MR and GR mRNA expression since no significant 
differences were found between groups CORT and CORT+FLX.  
 
3.4. Effects of treatments on serotonin 5-HT1A receptor  
Figure 3 reports 5-HT1A receptor mRNA levels and [
3H]-8-OH-DPAT binding 
densities as measured in the different experimental groups. Colour-coded images 
from autoradiograms illustrate areas where significant changes were detected. After 
chronic corticosterone treatment there was a decrease in 5-HT1A receptor mRNA 
levels in the DG (which reached statistical significance only in animals that received 
fluoxetine) (Fig. 3B) and in [3H]-8-OH-DPAT binding in the two groups treated with 
corticosterone (Fig. 3D). In contrast, in the dorsal raphe nucleus (DR) corticosterone 
elicited a fluoxetine-reversible decrease in 5-HT1A receptor mRNA expression (Fig. 
3C), while it did not affect [3H]8-OH-DPAT binding". 
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3.5. Effects of treatments on GIRK channel mRNA expression  
The expression of GIRK1, GIRK2 and GIRK3 subunit mRNA in several brain 
areas is reported in Fig. 4. Chronic hypercorticosteronemia significantly increased 
GIRK2 subunit mRNA expression in the ventromedial (VMH) and dorsomedial (DMH) 
hypothalamic areas.  However, concomitant fluoxetine treatment counteracted the 
effect of chronic corticosterone and GIRK2 mRNA levels remained indistinguishable 
from sham-controls. 
 
3.6. Effects of chronic treatments on granular layer of the dentate gyrus 
In order to quantitatively determine the potential effects that chronic 
hypercorticosteronemia might have on neuronal loss in our animal models, we 
measured the volume of the granular layer of the DG (DGgl) (see supplementary Fig. 
S4) in control, chronic corticosterone and chronic corticosterone with fluoxetine 
treated animals (n=5 each). Our volume calculations were in the range of 1.74±0.11 
to 1.87±0.10 mm3, and showed that neither corticosterone nor corticosterone with 
fluoxetine treatment caused significant differences among groups (supplementary 
Fig. S5). To further investigate the impact on structural integrity of DGgl, neuronal 
density was measured in the DGgl of the above-mentioned groups (supplementary 
Figs. S6 and S7). Once again we found no statistically significant effects of 
corticosterone or corticosterone with fluoxetine treatments on neuronal density in the 
DGgl.  
 
4. Discussion 
The present results support and extend previous observations showing that 
manipulation of corticosterone levels by slow-release corticosterone pellets produces 
a functional desensitization of somatodendritic 5-HT1A autoreceptors in dorsal raphe 
nucleus (DR) (Gartside et al., 2003a; Gartside et al., 2003b; Leitch et al., 2003). Our 
work provides novel and useful evidence regarding the regulation of cellular 
expression of mRNAs coding for the 5-HT1A receptor and GIRK1-3 subunits in this 
animal model and in particular during the concurrent administration of corticosterone 
and fluoxetine. As previously discussed (Gartside et al., 2003b; Holsboer, 2000; 
Young et al., 2004), interactions between corticosterone and fluoxetine may be 
critical in the origin of reduced antidepressant efficacy of selective serotonin reuptake 
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inhibitors (SSRIs) in patients with pre-existing abnormalities of the HPA axis. 
Moreover, we have monitored the expression patterns of the mRNAs coding for 
mineralocorticoid (MR) and glucocorticoid (GR) receptors at which the effects of 
corticosterone alone and plus fluoxetine were observed. 
The present experimental paradigm differs from that of Leitch et al. (2003), 
who used corticosterone pellets to provide continuous slow release of corticosterone 
in adrenally intact animals, both in terms of the daily dose being higher (25 mg/kg 
compared to 18 mg/kg) and in terms of treatment duration (35 days compared to 14 
days). However, the average daily dose of corticosterone, although did vary over the 
5 weeks because of increase in the body weight of the rats (25-31 mg/kg/day), was 
within the range used by Akana et al. (1992), Young et al. (1995) and Young (1996), 
and was slightly lower than that used by Meijer et al. (1997b). In accord with all the 
aforementioned studies, we found that the adrenal glands in rats treated for 35 days 
with corticosterone showed a degree of atrophy compared to controls, probably via a 
decrease in ACTH, the major determinant of adrenal weight via its trophic effects 
(Fig. 1). It is of note that the corticosterone treatment regime did not appear to 
adversely affect the general health of the animals, although corticosterone-treated 
animals were lighter at the end of the treatment period. This was accounted for by 
low weight gain 5 to 15 days after pellet implantation, and their weight gain was 
normal for the latter part of the treatment period (Fig. S3). Although, the regime of 
corticosterone treatment used here produced corticosterone levels (Fig. 1) that did 
not exceed the physiological levels, we cannot reject that probably some degree of 
hypercorticism could have taken place during the first week of treatment. In this 
context, thymus weight changes could have confirmed the potential hypercorticism.  
 
Effects of treatments on corticosteroid receptor mRNAs.  
Both MR and GR mRNA were abundant in the granule cell layer of the DG and 
the pyramidal cell layer of the Ammon’s horn (CA). However MR mRNA was present 
in all fields CA1-4 whereas GR mRNA was restricted to fields CA1-2. GR mRNA 
showed also a very strong labelling over the granule cell layer of the cerebellar cortex 
(CbGr). These patterns of hybridization agree with the previously described cellular 
distribution of the two types of corticosteroid receptors (Herman et al., 1989). 
Previous studies have shown that high doses of corticosterone trigger a down-
regulation of GR mRNA and GR protein in the CA1 subfield of the hippocampus 
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(Sapolsky and McEwen, 1985; Sarabdjitsingh et al., 2010), and removal of circulating 
glucocorticoids by adrenalectomy induces an up-regulation of GR mRNA and MR 
mRNA in CA1-2 subfields, which may be reversed by dexamethasone replacement 
(Herman et al., 1989). In our rat model, after 35 days of continuous corticosterone 
release, the MR and GR mRNA levels were significantly down-regulated in the DG 
and CA hippocampal areas and the CbGr, respectively. The lack of GR mRNA down-
regulation at the hippocampus is at odds with the aforementioned studies (Sapolsky 
and McEwen, 1985; Sarabdjitsingh et al., 2010), but agrees with previous studies 
that used comparable corticosterone pellets in adrenally intact rats (Akana et al., 
1992; Herman and Spencer, 1998; Young et al., 1995). Thus, unlike the 
corticosterone pellet treatment that produces a flat circadian rhythm of 
corticosterone, the chronic corticosterone injection paradigm produces a GR down-
regulation in the hippocampus (Sapolsky and McEwen, 1985), suggesting that 
physiological increases in corticosterone levels may not be sufficient to down-
regulate the GR. The differential pattern of MR and GR occupancy profiles by 
corticosterone (de Kloet and Reul, 1987; Reul and de Kloet, 1985) has led to the 
well-reasoned hypothesis that regulation of MR-dependent actions of corticosterone 
will take place primarily at the level of regulation of MR protein expression (de Kloet 
and Reul, 1987). Our data suggest that MR gene transcription in the hippocampal 
formation may be more sensitive to regulation by corticosterone than GR gene. This 
was also inferred from studies in which animals were subjected to unpredictable 
stress or corticosterone treatment for a considerable period (Herman and Spencer, 
1998; Lopez et al., 1998). Therefore, chronic corticosterone treatment-induced down-
regulation of MR is likely to be a result of autologous regulation of the MR gene 
expression, whereas in the case of GR mRNA, expression appears to be inhibited by 
corticosterone acting through both MR and GR (Herman and Spencer, 1998; Kalman 
and Spencer, 2002). In agreement with this view, overexpression of MR in the mice 
forebrain decreases the basal mRNA expression patterns of GR in the CA1 region 
(Rozeboom et al., 2007). 
Finally, it has been demonstrated that long-term fluoxetine administration 
increases the expression of MR (Bjartmar et al., 2000; Brady et al., 1992). However, 
it is important to note that most animal studies investigating fluoxetine effects are 
performed in animals under baseline conditions. Since many depressed patients with 
a pre-existing flattening of their glucocorticoid rhythm will be prescribed fluoxetine as 
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a treatment for their depression, this potential interaction may be of therapeutic 
importance. Our results show that long-term treatment with fluoxetine was unable to 
reverse the hippocampal down-regulation of MR mRNA expression induced by 
corticosterone. In this sense, previous studies show that flattened glucocorticoid 
rhythm compromises the ability of fluoxetine to elevate forebrain 5-HT levels 
(Gartside et al., 2003b), an effect that could be necessary for the up-regulation of 
corticosteroid receptors induced by fluoxetine, and that might explain the limited 
efficacy of fluoxetine in patients with abnormal HPA axis function (Young et al., 
2004).  
 
Effects of treatments on 5-HT1A receptor  
Our results show that chronic corticosterone administration without fluoxetine 
produces decreases in 5-HT1A receptor mRNA (in DR) and binding sites (only in DG), 
and it is noteworthy that concomitant fluoxetine treatment reverses the alterations on 
5-HT1A receptor mRNA levels in dorsal raphe and induces a significant decrease of 
this mRNA in the DG. It is well established that the 5-HT1A receptor is subject to 
strong glucocorticoid repression (Chalmers et al., 1993; Meijer et al., 1997a; Meijer et 
al., 1997b; Meijer and de Kloet, 1994; Mendelson and McEwen, 1992). Regulation of 
the 5-HT1A receptor gene at the transcriptional level has been studied by analysis of 
its promoter region, where hormone response elements have been described (Ou et 
al., 2001; Wissink et al., 2000). At present, two possible mechanisms have been 
demonstrated: via binding of corticosteroid receptors to a negative glucocorticoid 
responsive element (nGRE) (Ou et al., 2001), and via protein-protein interactions 
with transcription factors such as NF-κB and AP-1, which up-regulate 5-HT1A receptor 
gene transcription (Wissink et al., 2000). Thus, MR and GR are able to interact by 
forming heterodimers, whereas additional GR can repress 5-HT1A receptor gene 
transcription in the absence of DNA binding through direct protein-protein interactions 
with AP-1 and NF-kB. Both pharmacologic and gene knockout studies have provided 
evidence that MR is involved in corticosterone-induced repression of 5-HT1A receptor 
gene transcription (Meijer et al., 1997a; Rozeboom et al., 2007). In particular, 
knockout of the murine GR gene did not impair corticosterone-mediated repression of 
hippocampal 5-HT1A receptor mRNA suggesting that MR alone is sufficient for trans-
repression of the 5-HT1A receptor gene by glucocorticoids (Meijer et al., 1997a). 
In fact, on this molecular basis, and assuming that in our rat model the 
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decreases in MR mRNA result in decreased levels of the corresponding protein, we 
could expect an up-regulation of the 5-HT1A receptor mRNA expression. However, in 
the last decade, a family of transcriptional repressors of the basal expression of this 
serotonin receptor, Freud-1 and Freud-2, and its inhibition by increasing intracellular 
calcium levels has been characterized (Ou et al., 2003). Importantly, the effects of 
calcium were reversed by calmodulin or calcium/calmodulin-dependent kinase 
(CAMK) inhibitors (Ou et al., 2003). Previous data have shown reduced expression of 
CAMKII mRNA in the DG of rats following implantation of corticosterone pellets 
(Gartside et al., 2003a). Since chronic treatment with corticosterone could be 
modifying at least three molecular mechanisms operative at the promoter region of 
the 5-HT1A receptor gene (nGRE, NF-kB and Freud-1), future studies on the 
expression of the CAMKII and Freud-1 in serotonergic projection areas, such as 
hippocampus and hypothalamus, and their localization in 5-HT1A-positive cells might 
help to characterize the role of these transcriptional repressors of the 5-HT1A receptor 
gene in this rat model of flattened corticosterone rhythm. 
Another important issue involves the effects of concurrent administration of 
fluoxetine both on the expression of 5-HT1A receptor mRNA and binding levels. As 
previously discussed, interactions between corticosterone and fluoxetine may be 
critical in the origin of reduced antidepressant efficacy of SSRIs in those patients with 
pre-existing abnormalities of the HPA axis (Gartside et al., 2003b). Our results 
support the contention since the concurrent treatment with fluoxetine could only 
reverse the changes on 5-HT1A receptor mRNA levels in the DR. The mechanism for 
these preferential effects on somatodendritic 5-HT1A autoreceptors remains unclear.  
 
Effects of treatments on GIRK1-3 subunit expression. 
GIRK channels mediate the synaptic actions of numerous neurotransmitters in 
the mammalian brain and play an important role in the regulation of neuronal 
excitability in most brain regions through activation of various G protein-coupled 
receptors including the serotonin 5-HT1A receptor (Zgombick et al., 1989). In fact, 
GIRKs are the only effectors for 5 HT1A autoreceptors in the DR, although in other 
brain regions 5-HT1A receptors are frequently coupled to adenylate cyclise (De Vivo 
and Maayani, 1986; Luscher et al. 1997). Recently, we have demonstrated that the 
mRNAs encoding GIRK1-3 subunits are present in most 5-HT1A receptor mRNA-
expressing cells in hippocampus, cerebral cortex, septum and DR (Saenz del Burgo 
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et al., 2008). Since GIRK channels can act as effectors of 5-HT1A receptors, we 
intended to determine whether GIRK1-3 subunit expression is altered by 
corticosterone-treatment. We did not find significant effects, with the exception of 
increases in GIRK2 mRNA in hypothalamic areas, which are reversed by fluoxetine 
treatment. To date, there is only scarce evidence that GIRK1 and GIRK2 subunits 
may be under negative regulation at the transcriptional level by corticosterone 
(Fairchild et al., 2003; Muma and Beck, 1999). The GIRK1 gene contains a potential 
binding site for the glucocorticoid receptor (GRE) (Schoots et al., 1997), but the 
presence of hormone response elements in the promoter region of GIRK2 and 
GIRK3 subunit genes remains to be established. Taking into account that fluoxetine, 
at low micromolar concentrations, inhibits the GIRK channel activity of xenopus 
oocytes injected with GIRK1-2 subunit mRNAs (Kobayashi et al., 2003), it is plausible 
that during the chronic and concurrent administration of corticosterone and 
fluoxetine, the acute blocking actions of fluoxetine on GIRK channels also play a role 
in the regulation of the mRNAs coding for GIRK1-3 subunits. A number of G-protein-
coupled receptors have been shown to activate GIRK channels. In fact it has been 
shown that postsynaptic K+ conductance increase induced by specific agonists of 
GABA, adenosine A1, and serotonin 5-HT1A receptors, is markedly reduced or absent 
in mice lacking the GIRK2 channel (Luscher et al., 1997). Therefore, by 
downregulating GIRK rather than one specific receptor, fluoxetine could reduce the 
inhibitory inputs from a number of metabotropic receptors and could increase the 
excitability of DRN neurons in a greater extent than of hippocampal neurons. 
 
Relevance of 5-HT1A receptor changes in the dentate gyrus 
Regarding 5-HT1A receptor, the general consensus is that chronically elevated 
corticosterone down-regulates 5-HT1A receptors in the DG (Lopez et al., 1998; Meijer 
et al., 1997b; Meijer and de Kloet, 1994). Neuroanatomical studies have shown that 
prolonged (lasting for months) elevations of glucocorticoids, induced by chronic 
stress or high doses of corticosterone, are toxic to hippocampal neurons (Sapolsky, 
2004). This so-called “dendritic pruning” has been observed mainly for CA3 
pyramidal cells (Woolley et al., 1990), while granule cells of DG appear to be largely 
unaffected. More recently, cell loss has been shown among CA3 pyramidal neurons 
and DG granule cells (Sousa et al., 1999). Since the studies cited above used very 
large doses of glucocorticoids, it remains unclear whether more moderate doses (our 
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rat model) would cause similar effects. Interestingly, previous results in this animal 
model showed that MAP2b mRNA was reduced in CA3 but not in CA1 or DG 
(Gartside et al., 2003a). This finding would be consistent with a selective decrease in 
dendritic extent and/or synaptic strength in the CA3. The changes observed here are 
somehow selective -in terms of mRNA species (decreases in 5-HT1A receptor mRNA 
but unchanged GIRK mRNAs) and hippocampal region affected (DG versus CA3)- 
suggesting that moderate doses of corticosterone cause quite specific effects rather 
than generalized effects, such as loss of neurons or decrease in hippocampal 
volume. 
In the DG and CA3 field of the rat hippocampus the vast majority of 5-HT1A receptor-
expressing cells showed GIRK1-3 subunit mRNAs (Saenz del Burgo et al., 2008). 
Therefore, it is difficult to explain our data simply as a consequence of a partial loss 
of neurons in these areas. Our volume calculations are in line with previous studies in 
the adult rat (Bayer et al., 1982; Brummelte and Galea, 2010), and, in fact, there 
were no obvious volumetric changes or changes in overall cell number of the DGgl 
after treatment with corticosterone pellets (see supplementary Figs. S4-S7). In this 
sense, our findings are consistent with several studies that have shown neither 
volumetric changes nor changes in overall cell number of the hippocampus or 
dentate gyrus after treatment with corticosterone pellets or injections (Bodnoff et al., 
1995; Brummelte and Galea, 2010; Sousa et al., 1998). It is also established that 
glucocorticoid excess decreases neurogenesis in the adult DG (Cameron and Gould, 
1994). Much of that is due to the sensitivity of progenitor cells to glucocorticoids 
(Cameron and Gould, 1994). Fluoxetine stimulates proliferation of progenitor cells in 
the DG through a 5-HT1A receptor-dependent mechanism (Huang and Herbert, 2005; 
Santarelli et al., 2003). Interestingly, fluoxetine action is also dependent on the 
presence of a diurnal rhythm of corticosterone. Thus, flattening glucocorticoid levels 
by implanting a subcutaneous pellet, prevents the stimulating actions of fluoxetine 
(Huang and Herbert, 2006). Therefore, our data support that the postsynaptic effects 
of 5-HT on 5-HT1A receptors in the DG to modulate cell proliferation will be 
compromised after corticosterone treatment, being the concurrent fluoxetine 
treatment unable to restore the functionality of the 5-HT1A receptor signalling. As 
proposed (Huang and Herbert, 2006), these findings may point to a new approach to 
the problem of treatment resistance, or to improved therapeutic sensitivity to 
fluoxetine in depression. 
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Abbreviations used in text and figures 
 
5-HT  serotonin  
CbGr  granular layer of the cerebellum 
CA  pyramidal cell layer of the hippocampus (CA1, CA2, CA3) 
DG  dentate gyrus of the hippocampus 
DGgl  granular layer of the dentate gyrus  
DMH  dorsomedial hypothalamic area 
DR  dorsal raphe nucleus 
GIRK  G-protein inwardly rectifying potassium channel (Kir3) 
LC  locus coeruleus 
PFCx  prefrontal cortex 
PVN  paraventricular nucleus 
SO  supraoptic nucleus 
Sp  septum 
SSRIs   selective serotonin reuptake inhibitors 
Th  thalamus 
VMH  ventromedial hypothalamic nucleus 
 
 
  
 19 
 
 
References 
 
Akana, S.F., Scribner, K.A., Bradbury, M.J., Strack, A.M., Walker, C.D., Dallman, 
M.F., 1992. Feedback sensitivity of the rat hypothalamo-pituitary-adrenal axis and its 
capacity to adjust to exogenous corticosterone. Endocrinology 131, 585-594. 
Bayer, S.A., Yackel, J.W., Puri, P.S., 1982. Neurons in the rat dentate gyrus granular 
layer substantially increase during juvenile and adult life. Science 216, 890-892. 
Bjartmar, L., Johansson, I.M., Marcusson, J., Ross, S.B., Seckl, J.R., Olsson, T., 
2000. Selective effects on NGFI-A, MR, GR and NGFI-B hippocampal mRNA 
expression after chronic treatment with different subclasses of antidepressants in the 
rat. Psychopharmacology (Berl) 151, 7-12. 
Bodnoff, S.R., Humphreys, A.G., Lehman, J.C., Diamond, D.M., Rose, G.M., 
Meaney, M.J., 1995. Enduring effects of chronic corticosterone treatment on spatial 
learning, synaptic plasticity, and hippocampal neuropathology in young and mid-aged 
rats. J. Neurosci. 15, 61-69. 
Brady, L.S., Gold, P.W., Herkenham, M., Lynn, A.B., Whitfield, H.J., Jr., 1992. The 
antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing 
hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. 
Brain Res. 572, 117-125. 
Brummelte, S., Galea, L.A., 2010. Chronic high corticosterone reduces neurogenesis 
in the dentate gyrus of adult male and female rats. Neuroscience 168, 680-690. 
Cameron, H.A., Gould, E., 1994. Adult neurogenesis is regulated by adrenal steroids 
in the dentate gyrus. Neuroscience 61, 203-209. 
Chalmers, D.T., Kwak, S.P., Mansour, A., Akil, H., Watson, S.J., 1993. 
Corticosteroids regulate brain hippocampal 5-HT1A receptor mRNA expression. J. 
Neurosci. 13, 914-923. 
de Kloet, E.R., Reul, J.M., 1987. Feedback action and tonic influence of 
corticosteroids on brain function: a concept arising from the heterogeneity of brain 
receptor systems. Psychoneuroendocrinology 12, 83-105. 
De Vivo, M., Maayani, S. 1986. Characterization of the 5-HT1A receptor-mediated 
inhibition of forskolim-stimulated adenylate ciclase activity in guinea pig and rat 
 20 
 
hippocampal membranes. J. Pharmacol. Exp. Ther., 238: 248-253. 
Fairchild, G., Leitch, M.M., Ingram, C.D., 2003. Acute and chronic effects of 
corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe 
nucleus. Neuropharmacology 45, 925-934. 
Gartside, S.E., Leitch, M.M., McQuade, R., Swarbrick, D.J., 2003a. Flattening the 
glucocorticoid rhythm causes changes in hippocampal expression of messenger 
RNAs coding structural and functional proteins: implications for aging and 
depression. Neuropsychopharmacology 28, 821-829. 
Gartside, S.E., Leitch, M.M., Young, A.H., 2003b. Altered glucocorticoid rhythm 
attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the 
treatment of depression. Neuropsychopharmacology 28, 1572-1578. 
Gundersen, H.J., Jensen, E.B., 1987. The efficiency of systematic sampling in 
stereology and its prediction. J. Microsc. 147, 229-263. 
Herman, J.P., Patel, P.D., Akil, H., Watson, S.J., 1989. Localization and regulation of 
glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal 
formation of the rat. Mol. Endocrinol. 3, 1886-1894. 
Herman, J.P., Spencer, R., 1998. Regulation of hippocampal glucocorticoid receptor 
gene transcription and protein expression in vivo. J. Neurosci. 18, 7462-7473. 
Hervás, I., Vilaró, M.T., Romero, L, Scorza, C., Mengod, G., Artigas, F. 2000. 
Desentizitation of 5-HT1A autoreceptors by a low chronic fluoxetine dose effect of the 
concurrent administration of WAY-100635. Neuropsychopharmacol. 24, 11-20. 
Holmes, M.C., French, K.L., Seckl, J.R., 1995. Modulation of serotonin and 
corticosteroid receptor gene expression in the rat hippocampus with circadian rhythm 
and stress. Brain Res. Mol. Brain Res. 28, 186-192. 
Holsboer, F. 2000. The corticosteroid receptor hypothesis of depression. 
Neuropsychopharmacology 23, 477-501. 
Huang, G.J., Herbert, J., 2005. The role of 5-HT1A receptors in the proliferation and 
survival of progenitor cells in the dentate gyrus of the adult hippocampus and their 
regulation by corticoids. Neuroscience 135, 803-813. 
Huang, G.J., Herbert, J., 2006. Stimulation of neurogenesis in the hippocampus of 
the adult rat by fluoxetine requires rhythmic change in corticosterone. Biol. Psychiatry 
 21 
 
59, 619-624. 
Kalman, B.A., Spencer, R.L., 2002. Rapid corticosteroid-dependent regulation of 
mineralocorticoid receptor protein expression in rat brain. Endocrinology 143, 4184-
4195. 
Karten, Y.J., Nair, S.M., van, E.L., Sibug, R., Joels, M., 1999. Long-term exposure to 
high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 
neurons. Proc. Natl. Acad. Sci. U. S. A 96, 13456-13461. 
Kobayashi, T., Washiyama, K., Ikeda, K., 2003. Inhibition of G protein-activated 
inwardly rectifying K+ channels by fluoxetine (Prozac). Br. J. Pharmacol. 138, 1119-
1128. 
Leitch, M.M., Ingram, C.D., Young, A.H., McQuade, R., Gartside, S.E., 2003. 
Flattening the corticosterone rhythm attenuates 5-HT1A autoreceptor function in the 
rat: relevance for depression. Neuropsychopharmacology 28, 119-125. 
Lopez, J.F., Chalmers, D.T., Little, K.Y., Watson, S.J., 1998. A.E. Bennett Research 
Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in 
rat and human hippocampus: implications for the neurobiology of depression. Biol. 
Psychiatry 43, 547-573. 
Luscher, C., Jan, L.Y., Stoffel, M., Malenka, R.C., Nicoll, R.A. 1997. G protein-
coupled inwardly rectifying K+ channels (GIRK) mediate postsynaptic but not 
presynaptic transmitter actions in hippocampal neurons. Neuron, 19, 687-695 
Meijer, O.C., Cole, T.J., Schmid, W., Schutz, G., Joels, M., de Kloet, E.R., 1997a. 
Regulation of hippocampal 5-HT1A receptor mRNA and binding in transgenic mice 
with a targeted disruption of the glucocorticoid receptor. Brain Res. Mol. Brain Res. 
46, 290-296. 
Meijer, O.C., de Kloet, E.R., 1994. Corticosterone suppresses the expression of 5-
HT1A receptor mRNA in rat dentate gyrus. Eur. J. Pharmacol. 266, 255-261. 
Meijer, O.C., Van Oosten, R.V., de Kloet, E.R., 1997b. Elevated basal trough levels 
of corticosterone suppress hippocampal 5-hydroxytryptamine(1A) receptor 
expression in adrenally intact rats: implication for the pathogenesis of depression. 
Neuroscience 80, 419-426. 
Mendelson, S.D., McEwen, B.S., 1992. Autoradiographic analyses of the effects of 
adrenalectomy and corticosterone on 5-HT1A and 5-HT1B receptors in the dorsal 
 22 
 
hippocampus and cortex of the rat. Neuroendocrinology 55, 444-450. 
Muma, N.A., Beck, S.G., 1999. Corticosteroids alter G protein inwardly rectifying 
potassium channels protein levels in hippocampal subfields. Brain Res. 839, 331-
335. 
Ou, X.M., Lemonde, S., Jafar-Nejad, H., Bown, C.D., Goto, A., Rogaeva, A., Albert, 
P.R., 2003. Freud-1: A neuronal calcium-regulated repressor of the 5-HT1A receptor 
gene. J. Neurosci. 23, 7415-7425. 
Ou, X.M., Storring, J.M., Kushwaha, N., Albert, P.R., 2001. Heterodimerization of 
mineralocorticoid and glucocorticoid receptors at a novel negative response element 
of the 5-HT1A receptor gene. J. Biol. Chem. 276, 14299-14307. 
Parks, C.L., Robinson, P.S., Sibille, E., Shenk, T., Toth, M., 1998. Increased anxiety 
of mice lacking the serotonin1A receptor. Proc. Natl. Acad. Sci. U. S. A 95, 10734-
10739. 
Reul, J.M., de Kloet, E.R., 1985. Two receptor systems for corticosterone in rat brain: 
microdistribution and differential occupation. Endocrinology 117, 2505-2511. 
Rozeboom, A.M., Akil, H., Seasholtz, A.F., 2007. Mineralocorticoid receptor 
overexpression in forebrain decreases anxiety-like behavior and alters the stress 
response in mice. Proc. Natl. Acad. Sci. U. S. A 104, 4688-4693. 
Sáenz del Burgo, L., Cortés, R., Mengod, G., Zarate, J., Echevarría, E., Sallés, J., 
2008. Distribution and neurochemical characterization of neurons expressing GIRK 
channels in the rat brain. J. Comp Neurol. 510, 581-606. 
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, 
N., Lee, J., Duman, R., Arancio, O., Belzung, C., Hen, R., 2003. Requirement of 
hippocampal neurogenesis for the behavioral effects of antidepressants. Science 
301, 805-809. 
Sapolsky, R.M. 2004. Is impaired neurogenesis relevant to the affective symptoms of 
depression? Biol. Psychiatry 56, 137-139. 
Sapolsky, R.M., McEwen, B.S., 1985. Down-regulation of neural corticosterone 
receptors by corticosterone and dexamethasone. Brain Res. 339, 161-165. 
Sarabdjitsingh, R.A., Isenia, S., Polman, A., Mijalkovic, J., Lachize, S., Datson, N., de 
Kloet, E.R., Meijer, O.C., 2010. Disrupted corticosterone pulsatile patterns attenuate 
 23 
 
responsiveness to glucocorticoid signaling in rat brain. Endocrinology 151, 1177-
1186. 
Schoots, O., Voskoglou, T., Van Tol, H.H., 1997. Genomic organization and promoter 
analysis of the human G-protein-coupled K+ channel Kir3.1 (KCNJ3/HGIRK1). 
Genomics 39, 279-288. 
Sousa, N., Almeida, O.F., Holsboer, F., Paula-Barbosa, M.M., Madeira, M.D., 1998. 
Maintenance of hippocampal cell numbers in young and aged rats submitted to 
chronic unpredictable stress. Comparison with the effects of corticosterone 
treatment. Stress. 2, 237-249. 
Sousa, N., Paula-Barbosa, M.M., Almeida, O.F., 1999. Ligand and subfield specificity 
of corticoid-induced neuronal loss in the rat hippocampal formation. Neuroscience 
89, 1079-1087. 
Unceta, N., Barrondo, S., Ruíz, d.A., I, Gómez-Caballero, A., Goicolea, M.A., Sallés, 
J., Barrio, R.J., 2007. Determination of fluoxetine, norfluoxetine and their 
enantiomers in rat plasma and brain samples by liquid chromatography with 
fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852, 
519-528. 
Wissink, S., Meijer, O., Pearce, D., van Der, B.B., van Der Saag, P.T., 2000. 
Regulation of the rat serotonin-1A receptor gene by corticosteroids. J. Biol. Chem. 
275, 1321-1326. 
Woolley, C.S., Gould, E., McEwen, B.S., 1990. Exposure to excess glucocorticoids 
alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res. 531, 
225-231. 
Young, E.A. 1996. Sex differences in response to exogenous corticosterone: a rat 
model of hypercortisolemia. Mol. Psychiatry 1, 313-319. 
Young, E.A., Altemus, M., Lopez, J.F., Kocsis, J.H., Schatzberg, A.F., DeBattista, C., 
Zubieta, J.K., 2004. HPA axis activation in major depression and response to 
fluoxetine: a pilot study. Psychoneuroendocrinology 29, 1198-1204. 
Young, E.A., Kwak, S.P., Kottak, J., 1995. Negative feedback regulation following 
administration of chronic exogenous corticosterone. J. Neuroendocrinol. 7, 37-45. 
Zgombick, J.M., Beck, S.G., Mahle, C.D., Craddock-Royal, B., Maayani, S., 1989. 
Pertussis toxin-sensitive guanine nucleotide-binding protein(S) couple adenosine A1 
 24 
 
and 5-hydroxytryptamine1A receptors to the same effector systems in rat 
hippocampus: biochemical and electrophysiological studies. Mol. Pharmacol. 35, 
484-494. 
 
 
  
Role of the funding source 
Funding for this study was provided by Instituto de Salud Carlos III, Spanish Ministry of 
Science and Basque and Catalan Governments. These public entities had no further role in 
the study design, collection, analysis and interpretation of data; in the writing of the report; 
and in the decision to submit the paper for publication.  
 
Contributors 
RC and JS conceived the study and coordinated the project. RC, GM, GGC and JS designed 
the experimental protocols. LSB, MM, RC, and GGC carried out the experimental work, data 
collection, and statistical analyses. RC and JS wrote the final draft of the manuscript. All the 
authors discussed the results and approved the final manuscript.    
 
Conflict of interest 
All authors declare that they have no conflicts of interest 
 
Acknowledgements 
This work was supported by grants SAF2004-02784 and SAF-2006-10243 from the Spanish 
Ministry of Science, grants S-PE08UN29 and IT-332-10 from the Basque Government, grant 
2009SGR220 from the Catalan Government and the Instituto de Salud Carlos III, Centro de 
Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Centro de Investigación 
Biomédica en Enfermedades Neurodegenerativas (CIBERNED). Laura Saenz del Burgo and 
Mario Montaña were recipients of fellowship from the Basque Government and from the 
UPV/EHU respectively. We gratefully acknowledge Juan Manuel Rodriguez for technical 
assistance. 
 
 
 Figure 1 
 
 
 
Fig. 1.- Effects of corticosterone treatment on body weight gain, plasma 
corticosterone levels and adrenal glands weight. (A) Reduction in weight gain 
observed in both corticosterone (CORT) and corticosterone plus fluoxetine 
(CORT+FLX) treated rats in comparison to sham control animals (n=9-10) during 
days 5-15 (One-way ANOVA: F2,26=116.9, P<0.0001) and days 5-36 (One-way 
ANOVA: F2,26=102.5, P<0.0001). (B) Elevation in plasma corticosterone levels in both 
treated animal groups (n=8-10) (One-way ANOVA: F2,24=5.909, P=0.0082). 
(C) Reduction in adrenal gland weight after corticosterone treatment (with or without 
fluoxetine) (n=9-10) (One-way ANOVA: F2,26=13.58, p<0.0001). Data are 
mean±SEM. Tukey’s test: +P<0.05, *P<0.001 versus control.  
  
Figure 2  
 
 
Fig. 2.- Effects of corticosterone treatment on mineralocorticoid (MR) and 
glucocorticoid (GR) receptor mRNA expression. Microdensitometric 
measurements (mean±SEM, n=4 per group) of MR mRNA (A1) and GR mRNA (A2) 
levels in several brain areas after treatment with corticosterone alone (CORT) or in 
combination with fluoxetine (CORT+FLX). Two-way ANOVA analysis revealed 
significant effects on MR mRNA (treatment×region interaction F18,82=5.48, P<0.0001) 
and GR mRNA expression (effect of treatment F2,89=7.484, P=0.001). Results of 
Bonferroni posttest: XP<0.01; *P<0.001. Significant changes in hippocampal MR 
mRNA (DG and CA) and in GR mRNA in the cerebellum (CbGr) are shown in digital 
colour-coded images obtained from autoradiograms of coronal brain sections: (B1-
B3) MR mRNA and (C1-C3) GR mRNA. Arrows point to structures where average 
mRNA levels were significantly reduced. Bar=3 mm.  
Figure 3 
 
Fig. 3.- Effects of corticosterone treatment on serotonin 5-HT1A receptor mRNA expression and 
[3H]8-OH-DPAT binding. Microdensitometric measurements (mean±SEM, n=4 per group) of 5-HT1A 
receptor mRNA levels (A1) and [3H]8-OH-DPAT binding sites (A2) in several brain areas after 
treatment with corticosterone alone (CORT) or in combination with fluoxetine (CORT+FLX). Two-way 
ANOVA analysis revealed significant effects on 5-HT1A receptor mRNA expression (treatment×region 
interaction F12,63=5.48, P<0.0001) and on [3H]8-OH-DPAT binding densities (treatment×region 
interaction F10,54=3.771, P=0.0007). Results of Bonferroni posttest: *P<0.001. Corticosterone treated 
animals (CORT) showed a decrease in 5-HT1A receptor mRNA expression in the dorsal raphe nucleus 
(DR) that was reversible by fluoxetine (CORT+FLX). This combined treatment also reduced 5-HT1A 
receptor mRNA levels in the hippocampus (DG). In the DG corticosterone treatment also decreased 5-
HT1A receptor binding, but this effect was not reversed by fluoxetine. All changes are shown in digital 
colour-coded images obtained from autoradiograms of coronal brain sections: reductions in 5-HT1A 
receptor mRNA expression in DG (B1-B3) and DR (C1-C3), and also in receptor binding in DG (D1-
D3). Arrows point to structures where average mRNA levels or receptor binding were significantly 
reduced. Bar=3 mm. 
Figure 4 
 
 
 
 
Fig. 4.- Effects of corticosterone treatment on GIRK1, GIRK2 and GIRK3 mRNA 
expression. Microdensitometric measurements (mean±SEM, n=4 per group) of 
GIRK1 (A1), GIRK2 (A2) and GIRK3 (A3) mRNA levels measured in different brain 
areas in sham controls, and in animals treated with corticosterone alone (CORT) or 
in combination with fluoxetine (CORT+FLX). Two-way ANOVA analysis revealed 
significant effects on GIRK2 mRNA expression (treatment effect F2,81=10.31, 
P=0.0001). Bonferroni posttest indicated a significant  increase in GIRK2 mRNA 
expression in the hypothalamic ventromedial (VMH, +P<0.05) and dorsomedial 
(DMH, *P<0.001) nuclei elicited by corticosterone treatment, that was reversed by 
concomitant fluoxetine treatment. Changes in GIRK2 mRNA expression are shown in 
digital colour-coded images obtained from autoradiograms of coronal brain sections 
(B1-B3). Bar=3 mm. 
 
Supplementary Material: 
 
 
 
Supplementary Figure S1. Specificity controls of MR and GR oligonucleotide probes.  
The control tests illustrated here were performed using probes complementary to bases 3116-3160 
(A1) and 3356-3400 (A2-A4) of MR mRNA (GenBank acc. no. M36074.1), and bases 70-120 (B1) and 
2221-2265 (B2-B4) of GR mRNA (GenBank acc. no. M14053.1).  
Identical patterns of hybridization signal distribution are obtained when using separately two different 
33P-labeled oligonucleotide probes specific for MR mRNA (A1, A2) or for GR mRNA (B1, B2). 
Hybridization signal shown is abolished when washing is performed at 80°C (A3, B3). Hybridization of 
33P-labeled probe is prevented in the presence of an excess (50-fold) of the same unlabeled 
oligonucleotide probe in the incubation buffer (A4, B4). Bar= 5 mm. 
 
 
 
 
Supplementary Figure 2. Specificity controls of GIRK1-3 oligonucleotide probes.  
The control tests illustrated here were performed using probes complementary to bases 8-31 (A1) and 
137-181 (A2-A4) of GIRK1 mRNA (GenBank acc. no. U01071.1), bases 1401-1446 (B1) and 219-263 
(B2-B4) of GIRK2 mRNA (GenBank acc. no. AB073755.1), and bases 1398-1442 (C1) and 276-320 
(C2-C4) of GIRK3 mRNA (GenBank acc. no. L77929.1). 
Identical patterns of hybridization signal distribution are obtained when using separately two different 
33P-labeled oligonucleotide probes specific for GIRK1 mRNA (A1, A2), GIRG2 mRNA (B1, B2) or 
GIRK3 mRNA (C1, C2). Hybridization signal shown is abolished when washing is performed at 80°C 
(A3, B3, C3). Hybridization of 33P-labeled probe is prevented in the presence of an excess (50-fold) of 
the same unlabeled oligonucleotide probe in the incubation buffer (A4, B4, C4). Bar= 5 mm. 
  
  
 
Supplementary Figure 3. Daily weight control of animals over chronic treatment with 
corticosterone pellets (200 mg). See text for details on treatment groups. Every animal 
was weighted daily at 9 am. Chronic treatment (sham n=10; treated n=10; fluoxetine-treated 
n=9). Note that all animal groups treated with corticosterone lost more weight after surgery 
than the corresponding controls. Data are mean±SEM. 
 
 
 
 
 
 
Supplementary Figure 4. Steps of the image processing to measure the volume of the 
granular layer of the rat dentate gyrus. a: Micrograph of a Nissl-counterstained coronal 
section of the rat hippocampus; b: Binary image resulting from threshold operation; c: Binary 
image generated after removing particles outside the granular layer of the dentate gyrus. 
Scale bar=1 mm. 
 
 
 
 
 
 
 
Supplementary Figure 5. Volume of granular layer of the rat dentate gyrus. The bar 
graph shows mean values for the total volume of the granular layer of the left and right 
dentate gyri in sham control, chronic corticosterone and chronic corticosterone+fluoxetine-
treated groups. Data are mean±SEM (n=5 in all groups). No significant differences were 
observed among groups. 
 
 
 
 
 
Supplementary Figure 6. Depiction of counting boxes used for quantification of cell 
nuclei in the granular layer of the rat dentate gyrus. Upper panel: Schematic drawing of 
a coronal section of the rat hippocampus to depict counting boxes used for quantification of 
cell nuclei in the granular layer of the left and right dentate gyri in sham control, chronic 
corticosterone and chronic corticosterone+ fluoxetine-treated groups. Lower panel: 
Representa-tive ApoTome images of Hoechst-stained nuclei of the lateral and medial blades 
of the granular layer of the rat dentate gyrus used for quantification. CA1-3, fields CA1-3 of 
the Ammmon’s horn; cc, corpus callosum; cing, cingulum bundle; DGlb, lateral blade of 
dentate gyrus; DGmb, medial blade of dentate gyrus; ec, external capsule. Scale bars: upper 
500 µm; lower 100 µm. 
 
 
 
 
 
 
 
 
Supplementary Figure 7. Counting of Hoechst-stained nuclei in the granular layer of 
the rat dentate gyrus. The bar graph shows mean values for Hoechst-stained nuclei in the 
granular layer of the left and right dentate gyri in sham control, chronic corticosterone and 
chronic corticosterone + fluoxetine-treated groups. Data are expressed as number of cells 
per mm2. Data are mean±SEM (n=5 in all groups). No significant differences were observed 
among groups. 
